| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- SEC Filing
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price ta...
Item 1.01. Entry into a Material Definitive Agreement. On August 8, 2025, Harvard Bioscience, Inc. (the "Company") ente...